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(See the Major Article by Elbadawi et al on pages 493–501 and the Editorial Commentary by Pavia on pages 502–3.)
Background. During the 2014–2015 influenza season in the United States, 256 cases of influenza-associated parotitis were
reported from 27 states. We conducted a case-control study and laboratory investigation to further describe this rare clinical manifestation of influenza.
Methods. During February 2015–April 2015, we interviewed 50 cases (with parotitis) and 124 ill controls (without parotitis) with
laboratory-confirmed influenza; participants resided in 11 states and were matched by age, state, hospital admission status, and specimen collection date. Influenza viruses were characterized using real-time polymerase chain reaction and next-generation sequencing.
We compared cases and controls using conditional logistic regression. Specimens from additional reported cases were also analyzed.
Results. Cases, 73% of whom were aged <20 years, experienced painful (86%), unilateral (68%) parotitis a median of 4 (range,
0–16) days after onset of systemic or respiratory symptoms. Cases were more likely than controls to be male (76% vs 51%; P = .005). We
detected influenza A(H3N2) viruses, genetic group 3C.2a, in 100% (32/32) of case and 92% (105/108) of control specimens sequenced
(P = .22). Influenza B and A(H3N2) 3C.3 and 3C.3b genetic group virus infections were detected in specimens from additional cases.
Conclusions. Influenza-associated parotitis, as reported here and in prior sporadic case reports, seems to occur primarily with influenza
A(H3N2) virus infection. Because of the different clinical and infection control considerations for mumps and influenza virus infections,
we recommend clinicians consider influenza in the differential diagnoses among patients with acute parotitis during the influenza season.
Keywords. influenza; parotitis.
Acute parotitis is a classic sign of mumps virus infection [1];
however, parotitis can be caused by other viral pathogens including adenovirus, Coxsackie A viruses, echoviruses, Epstein-Barr
virus, human herpes virus 6, human immunodeficiency virus,
lymphocytic choriomeningitis virus, and parainfluenza viruses
1 and 3 [2]. Acute viral parotitis is typically uncomplicated and
resolves with supportive care [3].
Parotitis with influenza A virus infection was described
among 12 patients with illnesses during the 1975–1976 influenza
season in the United States [4] and in reports of sporadic cases
occurring in the United States [5, 6], Canada [7, 8], Chile [9],
and Spain [10]. These cases involved uncomplicated illness and

occurred among children and adults. However, the frequency of
occurrence, risk factors for development, and clinical manifestations of influenza-associated parotitis are not well described.
During December 2014, 5 cases of parotitis among patients
with laboratory-confirmed influenza were reported to the
Centers for Disease Control and Prevention (CDC). Surveillance
activities for non-mumps parotitis were established by multiple
state health departments, and patients with non-mumps parotitis were tested for influenza and other respiratory viruses. From
these case-finding activities, 256 cases of influenza-associated
parotitis occurred during October 2014–March 2015 and were
reported to the CDC. During February 2015, we initiated a
multistate case-control study to describe the clinical, epidemiologic, and viral risk factors for influenza-associated parotitis.
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On 9 January 2015, the CDC notified state and local health
departments of the occurrence of influenza-associated parotitis
using notifications sent to the Epidemic Information Exchange
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Laboratory Testing and Analysis

To be eligible for the case-control study, cases and controls
needed to have laboratory-confirmed influenza detected using
any test recommended for routine patient diagnosis, including
polymerase chain reaction (PCR)–based molecular testing, rapid
diagnostic tests, or viral culture [11]. Influenza virus infection
was confirmed and subtyped for all case and control specimens
at the CDC using real-time (RT)-PCR, with standard protocols.
CDC Influenza Division laboratories conducted next-generation sequencing of case and control specimens. Briefly,
we extracted RNA from specimens using the QIAmp Viral
486 • CID 2018:67 (15 August) • Rolfes et al

RNA extraction kit according to protocol (Qiagen, Hilden,
Germany) and amplified full influenza genomes [12] using the
Superscript III One-Step RT-PCR kit (Invitrogen, Carlsbad,
California). After quality control and normalization procedures, we prepared and indexed paired-end Illumina libraries
using the Nextera XT sample preparation kit (Illumina, San
Diego, California). We then pooled up to 96 libraries (92 samples, 1 positive control, and 3 negative controls) and generated
sequences using a MiSeq platform (Illumina). We assembled
sequences with at least 20× coverage into genomes using the
Iterative Refinement Meta Assembler [13]. We compared study
sequences to viral reference sequences and sequences from
other circulating viruses. Additionally, we used LABEL [14] to
determine the genetic group of the hemagglutinin (HA) gene
of influenza A(H3N2) viruses and conducted phylogenetic analysis using MEGA 6 [15].
Statistical Analyses

We compared cases and controls using conditional logistic
regression, with maximum likelihood methods, on matched
case-control sets. We used a conditional logistic regression
with exact methods to estimate the odds ratios (ORs) for the
comparison of influenza subtypes and influenza A(H3N2) HA
genetic groups, because of low frequencies of some genetic
groups. We conducted statistical analyses with SAS, version
9.3 (SAS Institute, Cary, North Carolina) and considered P values < .05 to be statistically significant.
RESULTS
Description of Cases

During October 2014–March 2015, 256 cases of influenza-associated parotitis were reported to CDC from 27 states
(California, Hawaii, Illinois, Indiana, Kansas, Kentucky, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Missouri,
New Hampshire, New Jersey, New York, North Carolina,
Oregon, Pennsylvania, Rhode Island, South Carolina, Texas,
Utah, Vermont, Virginia, Washington, West Virginia, and
Wisconsin). Among patients with sufficient data, the median
age was 13 years (73% of 234 patients aged <20 years) and 69%
(155/224) were male.
Among the 50 cases interviewed, parotid swelling was
described as unilateral (68%), painful (86%), and lasting a
median of 4 days (interquartile range [IQR], 3–6 days among
36 patients reporting symptom duration). Thirty-seven patients
(74%) self-reported being tested for mumps while ill with parotitis; all tests were negative at state public health laboratories.
The majority of cases (78%) had symptoms consistent with
influenza, including chills, cough, muscle aches, sore throat, and
feeling feverish, prior to onset of parotitis (median, 4 days prior;
IQR, 1–7 days; range, 1–16 days). Eleven cases (22%) reported
seeing a healthcare provider prior to the onset of parotitis. One
patient reported a complication of illness (ear infection) and
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and requested that states notify the CDC’s Influenza Division
when a case was identified. We defined a case as acute parotitis
in a patient with laboratory-confirmed influenza virus infection
with clinical diagnosis of parotitis from 1 October 2014 through
31 March 2015 (the study interval).
States identified cases in multiple ways, including unsolicited reports of cases from healthcare providers and Health Alert
Network notifications asking healthcare providers to notify
health departments if they saw patients fitting the case definition. Also, 2 states set up enhanced laboratory testing for nonmumps viruses among specimens submitted to state public
health laboratories for mumps testing. In addition, the CDC also
received unsolicited reports of cases from healthcare providers.
Cases with an available respiratory or oral specimen (nasopharyngeal, oropharyngeal, or buccal swab) obtained while the
individual was symptomatic were eligible to participate in the
case-control study. We defined a control illness as laboratory-confirmed influenza in a patient without acute parotitis during the
study interval and with an available respiratory or oral specimen.
Controls were selected among patients with influenza reported
through annual influenza surveillance activities conducted by
state public health departments. We aimed to match 3 controls
to each case by age group (<2, 2–4, 5–13, 14–19, 20–49, and
≥50 years), state of residence, outpatient or inpatient status, and
date of specimen collection (±3 weeks). Based on statistical power
calculations to detect a 20% difference in exposure frequency, we
aimed to enroll 50 cases and 150 matched controls. Study participation was open to all states; 11 states participated (Kansas,
Maine, Michigan, Minnesota, Missouri, New Hampshire, New
Jersey, Texas, Virginia, West Virginia, and Wisconsin). Among
states that had identified more than 10 eligible cases, we randomly enrolled 10 into the study. The CDC deemed the proposed
activities to be part of a public health response.
We developed a questionnaire to collect information regarding
patient demographic features; signs and symptoms of illness; vaccine, travel, and illness history; as well as exposure to antivirals,
antibiotics, and over-the-counter medications within 2 weeks of
illness onset. During February 2015–April 2015, we interviewed
cases and controls, or parents/guardians for those aged <18 years,
by phone after obtaining verbal informed consent.

1 patient reported testicular pain during his illness. Among 7
cases (14%) hospitalized, 2 patients were admitted to an intensive care unit, including 1 who was hospitalized prior to symptom onset. None of the patients died.
Case-Control Study

Laboratory Testing Among Additional Cases

In addition to the 50 cases included in the case-control study,
CDC received reports of 163 other cases of influenza-positive
parotitis that occurred in patients who provided either laboratory information or specimens for further testing. Of these
additional case reports, 162 with subtyping information were
all reported as influenza A(H3N2) virus infections. One patient
had parotitis associated with RT-PCR–confirmed influenza B
virus infection.
Next-generation sequencing was performed on 80 specimens
from the additional cases not included in the case-control study;
complete or partial sequences were available from 61 (76%)
specimens. Among these, all had A(H3N2) viruses detected,
including 58 (95%) classified as 3C.2a, 1 (2%) classified as 3C.3,
and 2 (3%) classified in the 3C.3b HA genetic group—both
reported among cases from Pennsylvania. Together with the

Table 1. Demographic Characteristics of Cases and Controls, Multistate Investigation of Influenza-Associated Parotitis, United States, 1 October 2014–31
March 2015
Cases (n = 50)
Characteristic
Age, years

Respondents

Controls (n = 124)
n (%)

50

Respondents

n (%)

Odds Ratio [95% Confidence Interval]a

P Valuea

124

<2

…

0 (0)

…

0 (0)

…

…

2–4

…

2 (4)

…

6 (5)

…

…

5–13

…

21 (42)

…

61 (49)

…

…

14–19

…

13 (26)

…

26 (21)

…

…

20–49

…

11 (22)

…

23 (19)

…

…

≥50

…

3 (6)

…

8 (6)

…

…

Sex

50

124

Male

…

38 (76)

…

63 (51)

3.0 [1.4, 6.3]

Female

…

12 (24)

…

61 (49)

Reference

…

1.3 [0.3, 4.9]

.74

Race

50

124

Black

…

3 (6)

…

9 (7)

White

…

42 (84)

…

110 (89)

Other/unknown

…

5 (10)

…

5 (4)

Ethnicity

.005

50

Reference

…

0.5 [0.1, 2.1]

.34

1.3 [0.4, 3.8]

.66

Reference

…

124

Hispanic

…

7 (14)

…

18 (15)

Non-Hispanic

…

43 (86)

…

106 (85)

a

Odds ratios, 95% confidence intervals, and P values from conditional logistic regression. No statistical comparison of age group was done because age group was used to set up the
matched case-control pairs.
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We enrolled 50 cases and 124 matched controls. Thirty-one
cases were matched with 3 or more controls each and 19 cases
were matched to at least 1 control each. Cases and controls did
not differ in race/ethnicity; however, cases were significantly
more likely to be male (Table 1). Significantly fewer cases
self-reported influenza-like illness than controls (Table 2).
Significantly more cases than controls self-reported facial swelling, gland swelling, and ear pain. Cases were less likely than
controls to have received an influenza antiviral medication
(27% vs 64%; OR, 0.2; 95% confidence interval [CI], 0.1, 0.4)
but more likely to have received an antibiotic during their illness
(65% vs 22%; OR, 9.9; 95% CI, 4.1, 23.9). Cases and controls
did not differ significantly regarding the presence of underlying
medical conditions and exposures to over-the-counter medications, influenza vaccination, mumps vaccination, or histories of
travel, illness, or hospitalization (Table 3).
Five cases (11% of 47 respondents) and 2 controls (2% of
118 respondents) reported having prior mumps virus infection
(OR, 9.3; 95% CI, 1.8, 68.8). This association remained when
adjusted for male sex (OR, 6.2; 95% CI, 1.0, 37.2) and may be
age dependent, as 4 of the 5 cases with prior mumps were adults.
While all control specimens were nasopharyngeal or oropharyngeal swabs, most case specimens (66%) were buccal
swabs. Influenza A(H3N2) viruses were the only identified

influenza virus from cases (100% of 50 specimens) and the
most common among controls (95% of 123 specimens; Table 4).
Thirty-two (63%) case and 108 (92%) control specimens had
complete or partial sequences from next-generation sequencing
for further analysis. Phylogenetic analysis identified influenza
A(H3N2) viruses in the 3C.3 and 3C.2a HA genetic groups;
3C.2a HA genetic group viruses were detected among all cases
and most controls, which was not statistically significantly different. Within the HA gene, we did not identify any nucleotide
changes in the case sequences compared with sequences from
controls. Nucleotide changes seen between case sequences and
influenza reference sequences were characteristic of the 3C.2a
HA genetic group [16].

Table 2. Clinical Characteristics and Symptoms of Illness Among Cases and Controls, Multistate Investigation of Influenza-Associated Parotitis, United
States, 1 October 2014–31 March 2015
Cases (n = 50)
Characteristic

Respondents
b

Controls (n = 124)
n (%)

Respondents

n (%)

Odds Ratio [95% Confidence
Interval]a

P Value a

49

25 (51)

122

109 (89)

0.15 [0.06, 0.35]

<.001

Self-report of testing for influenza

45

30 (67)

124

123 (99)

0.003 [<0.001, 0.05]

<.001

Self-report of testing for strep throat

43

18 (42)

113

50 (44)

Influenza-like illness

0.8 [0.3, 1.7]

.53

Self-reported symptoms
Fever/feverishc

49

32 (65)

122

115 (94)

0.1 [0.05, 0.4]

Chills

49

24 (49)

115

87 (76)

0.3 [0.2, 0.7]

.002

Muscle ache

47

18 (38)

119

83 (70)

0.3 [0.1, 0.6]

<.001

<.001

Headache

48

30 (63)

119

86 (72)

0.6 [0.3, 1.3]

.23

Cough

50

32 (64)

122

106 (87)

0.2 [0.1, 0.6]

.001

49

5 (10)

121

36 (30)

0.2 [0.07, 0.6]

.004

Shortness of breath

49

4 (8)

120

33 (28)

0.2 [0.05, 0.6]

.007

Sore throat/difficulty swallowing

49

27 (55)

121

79 (65)

0.6 [0.3, 1.2]

.17

Runny nose

46

23 (50)

121

75 (62)

0.6 [0.2, 1.2]

.12

Ear pain

48

19 (40)

119

26 (22)

2.3 [1.1, 4.8]

.03

Rash

49

5 (10)

122

10 (8)

0.9 [0.2, 3.4]

.87

Facial swelling

50

34 (68)

122

2 (2)

Gland swelling

50

36 (72)

113

29 (26)

41.7 [10.0, 174.6]

<.001

5.9 [2.7, 13.0]

<.001

Tongue swellingd

47

1 (2)

121

4 (3)

…

…

Discomfort with acidic foods

40

4 (10)

92

8 (9)

1.1 [0.2, 4.7]

.95

a

Odds ratios (ORs), 95% confidence intervals, and P values from conditional logistic regression. Reference group for OR is absence of symptom or condition.

b

Influenza-like illness defined as fever (≥100oF) or feeling feverish and cough and/or sore throat.

c

Temperature ≥100oF or self-report of feeling feverish.

d

OR for frequency of tongue swelling in cases compared with controls could not be estimated from the model.

32 sequences from the case-control study case specimens, 90
(97%) of the A(H3N2) viruses from patients with parotitis were
classified in the 3C.2a genetic group.
DISCUSSION

During the 2014–2015 US influenza season, 256 cases of influenza-associated acute parotitis occurred among residents of 27
states and were reported to CDC. Reported cases ranged widely
in age but occurred primarily among school-aged children.
Patients described painful facial swelling, consistent with acute
parotitis, which developed shortly after the onset of systemic
or respiratory symptoms. Swelling lasted a median of 4 days
before resolving. Seven cases were hospitalized during their
illness, including 2 patients who were admitted to the intensive
care unit.
Prior to the 2014–2015 influenza season, only 18 cumulative
cases of influenza-associated parotitis were reported during the
1975–1976, 1984–1985, 2004–2005, and 2007–2008 influenza
seasons in the United States, Canada, Chile, and Spain [4–10].
Additional laboratory testing revealed influenza A(H3N2) virus
infections in all cases tested (15/15). Furthermore, the predominant influenza viruses during these seasons were influenza
A(H3N2) viruses [17–20]. Additionally, circulating viruses
characterized during these seasons had evidence of antigenic
differences (drift) from prior circulating influenza A(H3N2)
viruses [18–20].
488 • CID 2018:67 (15 August) • Rolfes et al

Influenza A(H3N2) viruses were also the predominant
viruses circulating during the 2014–2015 influenza season
in North America and Europe. The majority of circulating
A(H3N2) viruses were antigenically and genetically drifted
from the influenza A(H3N2) component in the 2014–2015
Northern Hemisphere influenza vaccine and from prior circulating A(H3N2) viruses [21]. Further genetic characterization
of A(H3N2) viruses in the United States demonstrated that the
majority of the drifted viruses were in a newly emerged HA
genetic group, labelled 3C.2a. Other HA genetic groups of the
A(H3N2) viruses also circulated during the season, including
3C.2b, 3C.3, 3C.3a, and 3C.3b, with local variability [22]. The
3C.3 and 3C.3b viruses are closely related, yet distinct, from
3C.2a viruses in phylogenetic analysis, with several amino acid
changes at antigenic sites [16, 22, 23].
In addition to the cases reported to the CDC, cases of influenza-associated parotitis were also reported in Canada, England,
Scotland, and separately in Pennsylvania during the 2014–2015
influenza season [24–27]. Combined with our report, 99%
(258/261) of all patients with influenza-associated parotitis
reported during the 2014–2015 influenza season had influenza A virus infections and 95% (246/258) were infected with
A(H3N2) viruses. Though infrequent during the 2014–2015
season, parotitis was also described in 1 patient after influenza
A(H1N1pdm09), reported from Scotland [25], and in 1 patient
with B virus infection, reported here. Of the 246 A(H3N2)
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Wheezing

Table 3. Clinical History and Epidemiologic Exposures Among Cases With Influenza-Associated Parotitis and Controls, Multistate Investigation
of Influenza-associated Parotitis, United States, 1 October 2014–31 March 31 2015
Cases (n = 50)
Characteristic

Respondents
b

Controls (n = 124)

n (%)

Respondents

n (%)

Odds Ratio [95%
Confidence Interval]a

P Valuea

46

1 (2)

123

9 (7)

0.2 [0.03, 2.2]

.21

49

21 (43)

124

56 (45)

0.9 [0.4, 2.0]

.81

Asthma

49

11 (22)

123

30 (24)

1.0 [0.4, 2.5]

.97

Chronic obstructive pulmonary disease or chronic
lung condition

49

2 (4)

124

3 (2)

1.6 [0.2, 15.0]

.71

Experienced complication from illness
Has an underlying medical condition
Underlying medical conditions

Cardiovascular condition

49

3 (6)

124

2 (2)

5.2 [0.7, 39.2]

.11

Diabetes

49

3 (6)

124

5 (4)

1.3 [0.2, 7.1]

.76

Renal condition

49

0 (0)

124

3 (2)

...

...

Immunosuppressive condition

49

0 (0)

124

4 (3)

...

...

49

0 (0)

123

4 (3)

48

4 (8)

124

7 (6)

...
1.4 [0.3, 5.7]

...
.66

Rheumatoid arthritis

48

0 (0)

124

1 (1)

...

...

Sjogren’s syndrome

49

0 (0)

124

0 (0)

...

...

Other conditionc

47

0 (0)

124

1 (1)

...

...

Vaccination history
Influenza vaccine: 2013–2014 season

47

29 (62)

118

78 (66)

1.1 [0.5, 2.5]

.78

Influenza vaccine: 2014–2015 seasond

44

18 (41)

121

49 (40)

1.1 [0.5, 2.3]

.91

Measles–mumps–rubella vaccinatione

46

46 (100)

110

103 (94)

History of mumps virus infection

47

5 (11)

118

2 (2)

...
9.3 [1.8, 68.8]

...
.03

History of parotitis

46

3 (7)

120

5 (4)

2.3 [0.4, 11.7]

.33

Strep throat in past year

46

8 (17)

115

18 (16)

1.2 [0.4, 3.5]

.70

Skin/soft tissue infection in past year

49

3 (6)

123

3 (2)

Respiratory syncytial virus or mononucleosis in
past year

48

0 (0)

123

1 (1)

2.7 [0.4, 18.5]

Hospitalization for other illness in past year

46

3 (7)

119

10 (8)

0.7 [0.2, 2.9]

.58

Dentist/oral surgeon visit within 2 weeks before
illness f

48

3 (6)

123

5 (4)

1.7 [0.4, 8.6]

.50

...

...

.30
...

Sinus procedure within 2 weeks before illness

48

1 (2)

123

0 (0)

Travel within 2 weeks before illness

46

5 (11)

122

11 (9)

1.0 [0.3, 3.6]

.98

...

Aware of others with parotitis/mumps

42

2 (5)

115

3 (3)

1.8 [0.3, 12.6]

.57

a

Odds ratios (ORs), 95% confidence intervals, and P values from conditional logistic regression. Reference group for OR is absence of symptom or exposure. ORs and P values could not
be estimated for exposures that were not observed in or observed for 100% of either cases or controls.
b
Self-reported complication in the case was ear infection and among controls included pneumomediastinum, pneumonia, bronchitis, bronchiectasis, persistent cough, and hallucination
with fever.
c

Other conditions included hepatic disease.

d

Received influenza vaccine at least 2 weeks before symptom onset.

e

Reported receiving at least 1 dose of the measles–mumps–rubella vaccine.

f

Patient saw dentist/oral surgeon for procedure other than routine cleaning.

viruses, 114 were further sequenced and 96% (109/114) were
classified in the 3C.2a HA genetic group. Our case ascertainment
efforts identified 2 patients infected with A(H3N2) viruses in
the 3C.3b HA genetic group, both reported from Pennsylvania,
which had a greater proportion of 3C.3b viruses circulating than
other parts of the country [22], and 1 patient infected with an
A(H3N2) virus from the 3C.3 HA genetic group.
Our case-control study revealed a significant association of
parotitis with male sex. We are not aware of anatomical differences in male and female parotid glands that could account for
this association [28], and male predominance among patients
with mumps parotitis, to our knowledge, has not been described
[29–31]. The recent report from British Columbia, Canada, noted
88% (14/16) of cases were males [24]. Additionally, we found

an association between a history of prior mumps infection and
influenza-associated parotitis, mainly among adults; the etiology
and clinical relevance of this finding is unclear. Patients with
influenza-associated parotitis, more so than controls, were less
likely to receive influenza antiviral therapy but were more commonly given an antibiotic during their illness, possibly because
healthcare providers were concerned about bacterial etiologies of
parotitis. We do not know for certain whether antibiotics were
appropriate for a patient; however, nationally we see that antibiotics tend to be overprescribed for patients with influenza [32].
Our investigation is subject to limitations. First, interview
responses may be subject to recall errors because most participants were interviewed 1–3 months after their illnesses, and
misclassification might occur with self-reported exposures.
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Chemotherapy in past year
Neurologic/neurodevelopmental condition

Table 4. Virologic Characteristics of Influenza Virus Infection Among Cases With Influenza-Associated Parotitis and Controls, Multistate Investigation
of Influenza-associated Parotitis, United States, 1 October 2014–31 March 2015

Virologic Characteristic

Cases, n (%)

Controls, n (%)

50 (100)

117 (95)

Odds Ratio [95% Confidence
Interval]a

P Valuea

Influenza subtypeb
A(H3N2)
A(H1N1)pdm09
B

3.3 [0.6, >999]

0.28

0 (0)

1 (0.8)

Reference

…

0 (0)

5 (4)

Reference

…

Genetic group of influenza A(H3N2) virusesc
3C.2a

32 (100)

105 (97)

3C.3

0 (0)

3 (3)

Reference

3.8 [0.7, >999]

0.22
…

3C.3a

0 (0)

0 (0)

Reference

…

3C.3b

0 (0)

0 (0)

Reference

…

a

b

Subtyping could not be performed on specimens from 1 control.

c

Of the influenza A(H3N2) viruses detected, sequencing was successful for 32 case and 108 control specimens.

Second, no cases had laboratory evidence of mumps infections;
however, detection of mumps virus in buccal and serum specimens is challenging, particularly among vaccinated persons
[33–35]. So, while unlikely given that none of the cases had epidemiologic links to mumps outbreaks, we could not definitively
rule out mumps. Third, we used different strategies to find cases
and controls, and this differential ascertainment might have
contributed to observed differences in self-reported symptoms.
Fourth, case specimens were primarily buccal swabs, and control
specimens were nasopharyngeal or oropharyngeal swabs. Buccal
swabs are currently not an approved specimen type for clinical
influenza diagnostic testing; however, low cycle threshold values from case buccal swabs tested by RT-PCR suggest a large
amount of influenza virus was present (median cycle threshold, 29.1, range, 19.1–38.5 among 98 specimens). Fifth, while
influenza A(H3N2) virus was detected in all subtyped case specimens, fewer case than control specimens had complete genetic
sequences. Next-generation sequencing has a lower limit of
detection than RT-PCR; therefore, it is likely that case specimens
that could not be sequenced contained lower viral loads. This
might result from physiologic differences in viral shedding from
the parotid gland or with the timing of specimen collection during the course of illness. Finally, additional sequencing investigations of case buccal specimens are ongoing to determine what
bacterial pathogens may be codetected and whether these pathogens may contribute to the propensity to develop parotitis with
influenza virus infection [36].
Additional investigations of influenza-associated parotitis are
warranted to better understand the etiology and epidemiologic
features of this uncommon clinical finding. After finding few
epidemiologic risk factors in our study, we focused on describing the sequence differences in the influenza virus. Specifically,
we looked for differences in the virus’s HA gene because of this
gene’s role in viral attachment to host epithelial cells and its propensity for genetic change. We did not identify any changes in
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the HA gene that were specific to case viruses; however, detailed
sequence analysis of the 7 other influenza gene segments might
help further explain differences in the case and control influenza viruses. Furthermore, there may be host cell polymorphisms, environmental factors, or unmeasured exposures that
may be risk factors for influenza-associated parotitis. Further
studies would also be helpful to understand how influenza
viruses interact with epithelial cells on the parotid gland and
whether influenza viruses circulating in 2014–2015 had different tropism to the parotid gland.
We believe that this outbreak is reflective of increased occurrence
during the 2014–2015 season rather than an artifact of enhanced
surveillance and case finding efforts. Multiple independent reports
from public health departments and clinicians were received by
CDC’s Influenza Division and Division of Viral Disease’s mumps
investigation team prior to setting up nationwide active case finding. However, it is possible that influenza-associated parotitis was
detected more often because targeted mumps investigations and
reductions in mumps incidence during the past few decades has
made non-mumps parotitis easier to detect. Efforts to establish
population-based surveillance of influenza-associated parotitis
could help describe its incidence, associated complications, and the
public health impact during influenza seasons.
In conclusion, this outbreak of influenza-associated parotitis
is the largest ever reported. Compared with recruited controls
and broader virologic surveillance in the United States, influenza-associated parotitis seems to occur primarily with influenza
A(H3N2) virus infection, although it does not appear to be
exclusively associated with the newly emerged 3C.2a HA genetic
group of A(H3N2) viruses. Our findings suggest that including
influenza in the differential diagnoses among patients who present with acute parotitis may be prudent during influenza season,
particularly during seasons dominated by influenza A(H3N2)
virus infection and when respiratory symptoms precede parotitis. Testing for influenza would support appropriate treatment
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Odds ratios (ORs) and P values from conditional logistic regression using exact methods to estimate the OR. For the model of influenza subtype, we defined a common reference group
of influenza A(H1N1)pdm09 and B virus infections. For the model of influenza A(H3N2) genetic groups, we defined a common reference group of 3C.3, 3C.3a, and 3C.3b virus infections.

with influenza antiviral treatment, according to treatment
guidelines [37], and may also reduce inappropriate use of antibiotics. Additionally, differentiating mumps-associated parotitis
from influenza-associated parotitis is important from a public
health perspective. Currently, mumps is relatively uncommon
and prone to outbreaks. When mumps is suspected in a person,
an intensive public health response may be warranted, including contact tracing, vaccination clinics, and patient isolation. In
the United States, we experience annual widespread epidemics
of influenza, and such a public health response is not generally
needed. Due to these substantial differences, public health officials should consider influenza virus infection when investigating occurrences of parotitis during the influenza season.
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